EARNINGS AND TRADING: NYCE International takeover talks fall through
The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Samuel Heath & Sons PLC - Birmingham, England based shower and bathroom accessory manufacturer - Says revenue flat for the year ended March 31 at £14.8 million, slightly up year-on-year. "I reported at the half year that we anticipated a tougher second half and this proved to be the case," says Non-Executive Chair Anthony Buttanshaw. Company says US tariffs caused some customers to pause projects as construction costs increased, with "a pronounced effect of changes to the taxation system on international clients relocating to other countries" in the UK. Pretax profit falls to £375,000 from £1.2 million. Samuel Heath reports one-off exceptional items of £383,000. Also, cost of sales increases to £8.2 million from £7.9 million. Company recommends unchanged final dividend of 8.56 pence, with the previous interim dividend also remaining unchanged at 4.50p. Buttanshaw comments that "orders are down and the summer is expected to be difficult," adding: "It is expected that orders will improve again in September but there is much uncertainty looking forward." However, he notes: "We feel the restructure at the end of 2025 shapes the business well and leaves us in a strong position to build on the positive momentum that should come from our continuing sales and marketing campaigns in our key markets."
----------
Oxford BioDynamics PLC - Oxford, England-based biotechnology company that develops medical tests - Signs first commercial agreement with "a third party" for the use of cloud-based 3D genomics platform EpiSwitch Orion. The platform translates 2D genomes into 3D interactions and mechanistic understanding as part of a translational biomarker discovery programme in psoriatic arthritis. Says the agreement forms part of the UK government-funded OPTIMISE psoriatic arthritis translational research programme. Company will be paid for laboratory biomarker discovery work, genomic sequence processing and insight generation. "This agreement represents an important milestone for OBD and for EpiSwitch Orion," Chief Executive Officer Richard Compton comments. "Psoriatic arthritis patients currently face a trial-and-error process in finding the most effective biologic therapy...It is also significant for us commercially: this is the first time a partner has paid for access to Orion's capabilities. We are delighted to be supporting the OPTIMISE programme alongside three leading UK academic and clinical institutions. We estimate a significant untapped market with approximately 15,000 genomics principal investigators with samples, genomes and grant funding who would benefit from using our platform."
----------
NYCE International PLC - London-based provider of gaming technologies and services - Says revenue in the first half of 2026 more than tripled year-on-year to £384,000, having reported revenue of £467,000 for the 18 months ended December 31. Notes that it raised £150,000 through debt and equity and has a cash balance of £63,000 as of June 30, down from £73,000 at December 31. NYCE says that it has been in talks regarding a possible takeover offer for the past six months, but that these discussions have now concluded without agreement being reached. Notes that the valuation implied by the indicative offer "would have represented a significant premium to its current market value." Says it will need additional working capital in the near term, and is reviewing various strategic and financing alternatives.
----------
CyanConnode Holdings PLC - Cambridge, England-based developer of narrowband radio frequency mesh networks - Put up or shut up deadline for possible bid from Esyasoft Holding Ltd, a subsidiary of International Holding Co PJSC, is extended to 1700 BST on August 4. Says the prospective buyer has completed its due diligence process, and that both parties are finalising the remaining elements of the documentation process. Esyasoft's most recent revised offer values CyanConnode's share capital at £36.5 million, equivalent to 10.165p per share. CyanConnode's board has agreed that it would be willing to recommend this unanimously to shareholders, should Esyasoft make a firm offer.
----------
Copyright 2026 Alliance News Ltd. All Rights Reserved.